|
|
BY OUR PHARMA CORRESPONDENT
15 September,2005: The US Food and Drug Administration has issued a non-approvable letter to Pfizer's new osteoporosis therapy lasofoxifene.
Branded as Oporia, the drug is a selective estrogen receptor modulator for the prevention of osteoporosis.
Pfizer said in an official communique that the company will be reviewing its submission with the FDA and considering various possible courses of action.
BY OUR PHARMA CORRESPONDENT |